Solventum (NYSE:SOLV) reported second-quarter sales of $2.2 billion, reflecting a 9.5% organic growth compared to the previous year. The company attributed this growth to advanced customer orders worth approximately $125 million ahead of an ERP cutover and a one-time $100 million tariff refund. Solventum also plans to separate its Health Information Systems (HIS) business to enhance focus on medical technology markets.
The company’s gross margin increased to 60.1%, aided by the tariff refund, while operating income stood at $627 million. Earnings per share (EPS) reached $2.55, boosted by advanced orders and tariff refunds. For 2026, Solventum raised its organic sales growth outlook to 2.5%-3%, with adjusted EPS projected at $7.10-$7.20.
Chief Executive Officer Bryan Hanson indicated the company is on track to surpass its long-term plan earlier than expected. Quarterly performance in segments included $1.4 billion in MedSurg sales (8.9% organic growth), $396 million in Dental Solutions (15.2% organic growth), and $354 million in HIS (5.4% organic growth).
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
